147 related articles for article (PubMed ID: 8480806)
1. Four against infection.
Meyer C
Am J Nurs; 1993 Apr; 93(4):68-72. PubMed ID: 8480806
[No Abstract] [Full Text] [Related]
2. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
3. FDA guidance document on monitoring delayed adverse events a good first start.
Williams DA
Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
[No Abstract] [Full Text] [Related]
4. Drug safety. Gaps in the safety net.
Couzin J
Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
[No Abstract] [Full Text] [Related]
5. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
Shea LL; Hanson A; Guglielmetti TM; Levy K
Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
[No Abstract] [Full Text] [Related]
6. Reporting of adverse drug events: a key to postmarketing drug safety.
Rheinstein PH
Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
[No Abstract] [Full Text] [Related]
7. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
Seruga B; Sterling L; Wang L; Tannock IF
J Clin Oncol; 2011 Jan; 29(2):174-85. PubMed ID: 21135271
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
9. Postmarketing surveillance and reporting of adverse drug events.
Baer RK
S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
[No Abstract] [Full Text] [Related]
10. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
11. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
12. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
13. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
14. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
15. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
16. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
17. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
18. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
19. US Food and Drug Administration: adverse event reporting.
Graham AA
CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
[TBL] [Abstract][Full Text] [Related]
20. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
[Next] [New Search]